



European Federation of Pharmaceutical
Industries and Associations

Transparency - working with patient groups

Richard Bergström (LIF Sweden)
Chair, EFPIA Code Steering Group

International Pharma Congress, May 2009, Rome

Background

- Support for a regulatory and political environment which stimulates R&D, rewards innovation and speeds up patient access to innovative therapies.
- Establish patient-centred approach and take into account patient needs in pharmaceutical company policies.
- Empower patient groups to be involved, informed and sustainable in the long-term.

Background: codes across the EU

- Binding codes of conduct in: UK, Sweden, Netherlands, Ireland, Denmark
- Codes were under way in Germany, Belgium
- Government legislation in France
- Company initiatives (GSK..)

Scope/ Applicability code

- Relationships between EFPIA member companies, their subsidiaries, contracted 3rd parties and patient groups operating in Europe
- Minimum standards
- Partnerships at national level: national code of country where activity takes place
- Cross-border partnerships: national code of country of main European location patient group

Enforcement code

- Member associations to implement code at national level and decide on processing complaints and sanctions
- As of 1 January 2008

Provisions code

Content:

- Non-promotion
- Written agreements
- Use of logos and proprietary materials
- Editorial control
- Transparency
- Single company funding
- Events and hospitality

Written agreements

- Ensuring clarity role between industry & patient groups
- In some countries available (upon request or database)
- Clear and simple document
- Model template in annex

Transparency

- Companies to make publicly available a list of sponsored patient groups once a year (incl. significant indirect/non-financial support)
- For the first time no later than end of 1st Q 2009 (covering activities commenced as of or ongoing on 1 January 2008)
- Review after first year of implementation

Relationships

*between the
Pharmaceutical Industry
and
Patient Organisations*



efpia

European Federation of Pharmaceutical
Industries and Associations

Leopold Plaza Building
Rue du Trône 108 - box 1
B- 1050 Brussels
Tel: +32 (0)2 626.25.71
e-mail: info@efpia.org

www.efpia.eu

CODE OF PRACTICE

efpia
European Federation of Pharmaceutical
Industries and Associations

efpia

OUR COMMITMENT IN 7 POINTS

- 1 **Non-promotion**
 - > EU and national legislation and codes of practice apply
- 2 **Clarity**
 - > written agreements defining pharmaceutical companies' support
- 3 **Use of Logos**
 - > written permission for the use of logos or materials
- 4 **Editorial Control**
 - > no influence of editorial content to favour commercial interests
- 5 **Transparency**
 - > information about who pharmaceutical companies support and how
- 6 **Diversified Funding**
 - > encourage multiple sources of funding for patient organisations
- 7 **Reasonable Hospitality**
 - > hospitality limited to a reasonable level



 More information on www.efpia.eu

EFPIA'S BINDING ETHICAL STANDARDS



- > The pharmaceutical industry has many interests in common with patient organisations, which represent and/or support the needs of patients and/or caregivers.
- > By working with patient organisations, the pharmaceutical industry is better able to understand and address patient needs and concerns on research and medicines.
- > Industry funding to patient organisations helps to support programmes that improve the lives of people with a wide range of medical conditions.



As of 1 July 2008, the **EFPIA Code of Conduct on Relationships between the Pharmaceutical Industry and Patient Organisations** will apply to the 1,200 companies EFPIA represents directly and indirectly across Europe, including companies that are members of EFPIA's specialised groups EBE (European Biopharmaceutical Enterprises) and EVM (European Vaccine Manufacturers).



National structures and procedures will be in place to process complaints and impose sanctions, in which non-industry stakeholders will be represented. Publication of the names of patient organisations supported by the pharmaceutical industry will take place no later than 1 April 2009. A review of the Code will be initiated after the first year of implementation.